AIGH Capital Management LLC Has $8.73 Million Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

AIGH Capital Management LLC grew its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 17.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,574,846 shares of the company's stock after buying an additional 389,192 shares during the period. Xeris Biopharma makes up 2.7% of AIGH Capital Management LLC's portfolio, making the stock its 15th largest position. AIGH Capital Management LLC owned approximately 1.73% of Xeris Biopharma worth $8,729,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. R Squared Ltd acquired a new position in Xeris Biopharma in the fourth quarter valued at about $42,000. Cibc World Markets Corp acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at approximately $44,000. Raymond James Financial Inc. acquired a new stake in Xeris Biopharma during the 4th quarter worth approximately $45,000. Quantbot Technologies LP bought a new position in Xeris Biopharma in the third quarter valued at approximately $44,000. Finally, Virtu Financial LLC acquired a new position in shares of Xeris Biopharma in the fourth quarter valued at approximately $58,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Insider Activity at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.56% of the stock is owned by company insiders.

Remove Ads

Wall Street Analyst Weigh In

XERS has been the topic of a number of research analyst reports. Piper Sandler restated a "neutral" rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Leerink Partners boosted their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. Jefferies Financial Group reiterated a "buy" rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Craig Hallum boosted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research note on Friday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $6.10.

Xeris Biopharma Stock Down 4.7 %

Shares of NASDAQ:XERS traded down $0.24 during midday trading on Thursday, reaching $4.91. The company had a trading volume of 1,115,460 shares, compared to its average volume of 2,656,927. The business's 50 day moving average price is $4.25 and its 200 day moving average price is $3.57. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.69 and a 1-year high of $6.07. The stock has a market cap of $755.85 million, a PE ratio of -10.91 and a beta of 1.37.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.